Factors contributing to the efficacy of two add-on therapies of fesoterodine or mirabegron to silodosin monotherapy for persistent overactive bladder in men with lower urinary tract symptoms

被引：2
|
作者：
Matsukawa, Yoshihisa [1 ]
Gotoh, Momokazu [1 ]
机构：
[1] Nagoya Univ, Dept Urol, Grad Sch Med, Nagoya, Aichi, Japan
来源：
INTERNATIONAL JOURNAL OF UROLOGY | 2020年 / 27卷 / 01期
关键词：
D O I：
10.1111/iju.14117
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：85 / 86
页数：2
相关论文
共 50 条
  • [1] Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving a-blocker treatment for lower urinary tract symptoms
    Kaplan, Steven A.
    Roehrborn, Claus G.
    Gong, Jason
    Sun, Franklin
    Guan, Zhonghong
    BJU INTERNATIONAL, 2012, 109 (12) : 1831 - 1840
  • [2] Mirabegron Add-on Therapy to Tamsulosin for the Treatment of Overactive Bladder in Men with Lower Urinary Tract Symptoms: A Randomized, Placebo -controlled Study (MATCH)
    Kakizaki, Hidehiro
    Lee, Kyu-Sung
    Yamamoto, Osamu
    Jong, Jar Jar
    Katou, Daisuke
    Sumarsono, Budiwan
    Uno, Satoshi
    Yamaguchi, Osamu
    EUROPEAN UROLOGY FOCUS, 2020, 6 (04): : 729 - 737
  • [3] Cardiovascular safety of mirabegron add-on therapy to tamsulosin for the treatment of overactive bladder in men with lower urinary tract symptoms: A post hoc analysis from theMATCHstudy
    Katoh, Takao
    Kakizaki, Hidehiro
    Lee, Kyu-Sung
    Ishida, Kota
    Katou, Daisuke
    Yamamoto, Osamu
    Jong, Jar Jar
    Sumarsono, Budiwan
    Uno, Satoshi
    Yamaguchi, Osamu
    LUTS-LOWER URINARY TRACT SYMPTOMS, 2021, 13 (01) : 98 - 107
  • [4] A randomized controlled study of the efficacy of tadalafil monotherapy versus combination of tadalafil and mirabegron for the treatment of persistent overactive bladder symptoms in men presenting with lower urinary tract symptoms (CONTACT Study)
    Yamanishi, Tomonori
    Kaga, Kanya
    Sakata, Koichi
    Yokoyama, Teruhiko
    Kageyama, Shinji
    Fuse, Miki
    Tokunaga, Shoji
    NEUROUROLOGY AND URODYNAMICS, 2020, 39 (02) : 804 - 812
  • [5] Efficacy and safety of add-on mirabegron vs placebo to tamsulosin in men with overactive bladder symptoms (match study)
    Lee, K-S.
    Kakizaki, H.
    Yamamoto, O.
    Jong, J. J.
    Katou, D.
    Sumarsono, B.
    Uno, S.
    Yamaguchi, O.
    INTERNATIONAL JOURNAL OF UROLOGY, 2019, 26 : 65 - 65
  • [6] EFFICACY AND SAFETY OF ADD-ON MIRABEGRON VS. PLACEBO TO TAMSULOSIN IN MEN WITH OVERACTIVE BLADDER SYMPTOMS (MATCH STUDY)
    Kakizaki, Hidehiro
    Lee, Kyu-Sung
    Yamamoto, Osamu
    Jong, Jar Jar
    Katou, Daisuke
    Sumarsono, Budiwan
    Uno, Satoshi
    Yamaguchi, Osamu
    JOURNAL OF UROLOGY, 2018, 199 (04): : E988 - E988
  • [7] Solifenacin as Add-on Therapy for Overactive Bladder Symptoms in Men Treated for Lower Urinary Tract Symptoms-ASSIST, Randomized Controlled Study
    Yamaguchi, Osamu
    Kakizaki, Hidehiro
    Homma, Yukio
    Takeda, Masayuki
    Nishizawa, Osamu
    Gotoh, Momokazu
    Yokoyama, Osamu
    Seki, Narihito
    Yoshida, Masaki
    UROLOGY, 2011, 78 (01) : 126 - 133
  • [8] Comparison in the efficacy of fesoterodine or mirabegron add-on therapy to silodosin for patients with benign prostatic hyperplasia complicated by overactive bladder: A randomized, prospective trial using urodynamic studies
    Matsukawa, Yoshihisa
    Takai, Shun
    Majima, Tsuyoshi
    Funahashi, Yasuhito
    Sassa, Naoto
    Kato, Masashi
    Yamamoto, Tokunori
    Gotoh, Momokazu
    NEUROUROLOGY AND URODYNAMICS, 2019, 38 (03) : 941 - 949
  • [9] Management of overactive bladder and lower urinary tract symptoms in men
    Hamilton J.N.
    Rovner E.S.
    Current Bladder Dysfunction Reports, 2008, 3 (2) : 117 - 122
  • [10] Treatment of men with lower urinary tract symptoms and overactive bladder
    Bell, William Andrew
    Amarshi, Naseem
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2007, 297 (11): : 1192 - 1192
12345